SCHEMBL10034895

SCHEMBL10034895

COc1cc(C(=O)Nc2ccc(S(N)(=O)=O)c(OC)c2)ccc1-c1ccccc1C(F)(F)F

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
POLB P06746 2/20 0.53
STAT3 P40763 1/20 0.48
GAA P10253 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MCL1 Q07820 1/20 0.47
LMNA P02545 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.46
NPC1 O15118 1/20 0.45
NQO2 P16083 1/20 0.45
CASP3 P42574 1/20 0.45
RAB9A P51151 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10035267 0.95 MAPT (0.49) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10035052 0.95 MAPT (0.48) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10035102 0.94 MAPT (0.47) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10034900 0.93 MAPT (0.48) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10035066 0.93 MAPT (0.48) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10035113 0.93 MAPT (0.50) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10034897 0.92 MCHR1 (0.46) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10034983 0.92 MAPT (0.48) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10035073 0.92 MAPT (0.48) MAPTPOLBSTAT3GAAMEN1
SCHEMBL10034979 0.91 MAPT (0.47) MAPTPOLBSTAT3GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594554-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-05-09 US disclosed
WO-2012008435-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 大日本住友製薬株式会社 (JP) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116227-A1 BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF MC2R, NR3C2, REN MAPT 4709/4885POLB 4291/4885STAT3 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.